Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level Bio ABFRA:4MB +7.41%23 EV-to-EBITDA is -34.13 as of Jul. 29, 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 847456.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Level Bio AB's enterprise value is €1.64 Mil.
Level Bio AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.05 Mil. Therefore, Level Bio AB's EV-to-EBITDA for today is -34.13.
The historical rank and industry rank for Level Bio AB's EV-to-EBITDA or its related term are showing as below:
FRA:4MB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.46 Med: -7.49 Max: -1.48
Current: -34.4
During the past 13 years, the highest EV-to-EBITDA of Level Bio AB was -1.48. The lowest was -41.46. And the median was -7.49.
FRA:4MB's EV-to-EBITDA is ranked worse than 100% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.53
vs FRA:4MB: -34.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Level Bio AB (FRA:4MB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Level Bio AB's PE Ratio (TTM) for today is calculated as:
Level Bio AB's share price for today is €0.0145.
Level Bio AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Level Bio AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4MB vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Level Bio AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Level Bio AB's EV-to-EBITDA falls into.
Level Bio AB's current Enterprise Value is €1.64 Mil.
Level Bio AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB (FRA:4MB) has a EV-to-EBITDA of -34.13 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Level Bio AB. According to the industry distribution chart, Level Bio AB ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry.
Is Level Bio AB's EV-to-EBITDA too high?
Level Bio AB's current EV-to-EBITDA is -34.13. Based on the distribution chart, Level Bio AB ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #999999 out of 118 companies for EV-to-EBITDA. This places Level Bio AB in the lower half of its industry. The industry median EV-to-EBITDA is 15.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.53, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Level Bio AB. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current EV-to-EBITDA is -34.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current EV-to-EBITDA of -34.13. The current EV-to-EBITDA is -34.13. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current EV-to-EBITDA is -34.13 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
